Ipamorelin dosing — trial doses vs the commonly reported range

There are two entirely separate sets of numbers, and they do not match. The doses tested in humans were intravenous: 4.21–140.45 nmol/kg as a 15-minute infusion in a healthy-volunteer pharmacology study (Gobburu et al., Pharm Res 1999), and 0.03 mg/kg twice daily in the only efficacy trial — roughly 2,100 mcg per dose for a 70 kg adult (Beck et al., Int J Colorectal Dis 2014). The figures circulating in research and community contexts are subcutaneous and roughly an order of magnitude smaller: 100–300 mcg per administration, one to three times daily. FDA stated in 2024 that it identified no pharmacokinetic or pharmacodynamic information for the subcutaneous route at all (FDA briefing document, 2024).

• 4.21, 14.04, 42.13, 84.27, and 140.45 nmol/kg IV — five escalating single doses, six healthy men per group, given over 15 minutes. The lowest dose produced negligible GH and was dropped from the analysis (Gobburu 1999).

• 0.03 mg/kg IV twice daily, postoperative day 1 through day 7 or discharge — the phase 2 postoperative ileus trial in 114 bowel-resection patients, which missed its primary endpoint (Beck 2014).

• 0.03 mg/kg twice daily, 0.06 mg/kg twice daily, and 0.06 mg/kg three times daily — the arms of a 320-patient dose-finding study that completed in 2014 (NCT01280344). No results were posted to the registry and no publication followed, so what those higher doses did is not in the public record.

A 200 mcg subcutaneous injection is about a tenth of the per-dose amount used in the trial that failed — and it is given by a different route, one with no published absorption data. That makes the comparison unreliable in both directions: nobody can say from the literature whether a community dose produces a smaller GH pulse, a similar one, or an unpredictable one.

What the human pharmacology does establish is that the GH response is dose-related but self-limiting. Across the full 33-fold IV dose range, GH rose to a sharp peak and fell to very low concentrations by 6 hours at every dose — a single episode of release per administration, not a sustained elevation (Gobburu 1999).

Ipamorelin has a terminal half-life of about 2 hours, systemic clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg, with a GH peak roughly 40 minutes after infusion. Those numbers explain the emphasis on timing in every protocol discussion: the drug is present briefly, so when it is given determines which of the body's natural GH pulses it reinforces.

Two mechanistic constraints follow. Because a secretagogue only works through a responsive pituitary, FDA's reviewers raised the concern that responsiveness can decline as GH stores are depleted with prolonged exposure — the pharmacological version of the tolerance community logs describe. And because peptides are digested, the compound is injected rather than swallowed; the delivered amount depends on how the powder was reconstituted, which is a common source of error when syringe units are read as if they were micrograms.

Absent a label, nobody is checking the two things that actually determine risk: what is in the vial, and whether raising GH is a bad idea for the person injecting it. On the first, FDA found the available certificates of analysis report purity but not impurities, aggregates, or endotoxins. On the second, GH secretagogues affect glucose handling — fasting glucose rose and insulin sensitivity fell over two years of MK-677 in older adults (Nass et al., Ann Intern Med 2008) — which is exactly the kind of interaction a clinician can monitor and a protocol from a forum cannot.

For the safety picture in full, see ipamorelin side effects; for what the studies did and did not show, see the research and evidence overview.